FICHIT

Je m'inscris

TXCELL

0/5 (0 note(s))
Note donnée : aucune
Paris
70
TxCell is developing innovative, personalized cell immunotherapies using regulatory T-cells (Treg) for severe chronic inflammatory and autoimmune diseases.
Ovasave® is TxCell lead product candidate derived from TxCell's proprietary platform ASTrIA. Ovasave® is a personalized T cell immunotherapy product, based on the properties of autologous ovalbumin-specific regulatory T lymphocytes. A phase IIb placebo controlled study has been initiated in refractory Crohn's Disease patients. This follows a phase I/IIa study in the same patient population, which has been successfully completed and reported positive clinical efficacy and good tolerability.
BOISSEL Stéphane
www.txcell.com
TXCL:FP

Fiche créée le 10/04/2016 par Guillaume   vue 5 fois.